UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 28, 2005
Hana Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-32626 | 32-0064979 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
400 Oyster Point Blvd., Ste. 215, South San Francisco, CA | 94080 |
| (Address of principal executive offices) | (Zip Code) |
(650) 588-6404
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into Material Definitive Agreement.
On December 28, 2005, Hana Biosciences, Inc. (the “Company”) and Russell L. Skibsted, the Company’s Chief Financial Officer until December 31, 2005, entered into a Separation Agreement (the “Agreement”). The Company had previously disclosed under Item 5.02 in its Current Report on Form 8-K dated December 14, 2005 (filed December 20, 2005) that it and Mr. Skibsted had agreed that Mr. Skibsted’s employment with the Company would end December 31, 2005. The Agreement memorialized such agreement, confirmed certain terms of Mr. Skibsted’s employment agreement, including the compensation to which he is entitled following the termination of his employment with the Company, provided that the Company will pay to Mr. Skibsted additional aggregate consideration of $25,000 and provided for Mr. Skibsted’s release of any possible legal claims against the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | Hana Biosciences, Inc. |
|
|
|
| Date: January 3, 2006 | By: | /s/ John P. Iparraguirre |
| | John P. Iparraguirre |
| | Vice President, Chief Financial Officer |
